Macimorelin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Macimorelin: From Growth Hormone Deficiency Diagnosis to Hypertrichosis
One-Sentence Summary
Macimorelin is a ghrelin receptor agonist known clinically as a diagnostic agent for adult growth hormone deficiency (not a treated disease indication in this evidence pack). The TxGNN model predicts it may be effective for Hypertrichosis, but currently no clinical trials and no relevant literature support this direction — the prediction rests on knowledge-graph inference alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Diagnostic test for adult growth hormone deficiency (based on known drug class; not formally recorded in this evidence pack — MOA and indication fields are data gaps) |
| Predicted New Indication | Hypertrichosis |
| TxGNN Prediction Score | 98.31% |
| Evidence Level | L5 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, macimorelin is a ghrelin receptor agonist, clinically used as a diagnostic test (not a chronic treatment) for adult growth hormone deficiency, and mechanistically might theoretically relate to hair growth pathways given ghrelin’s broader roles in endocrine and metabolic signaling.
However, this mechanistic link is speculative, not evidence-based. There is no growth-hormone-axis or ghrelin-receptor literature specifically connecting macimorelin to hypertrichosis in the evidence pack, and no clinical trials exist for this drug-disease pair. The high TxGNN score (98.31%) reflects graph-structural similarity (e.g., macimorelin clustering near other hair-growth-associated nodes, as seen across ranks 1, 2, and 5 of the prediction list — hypertrichosis, Ambras syndrome, and isolated hair shaft abnormality), rather than a substantiated pharmacological hypothesis.
Given that macimorelin is fundamentally a short-acting diagnostic agent rather than a chronic therapeutic, its suitability for a cosmetic/dermatologic condition like hypertrichosis (which would require sustained treatment) is mechanistically questionable even before considering the lack of evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
Macimorelin currently has no EU marketing authorizations on record (market status: Not Marketed; total licenses: 0).
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite a high TxGNN score, this candidate has zero supporting clinical trials or literature, no confirmed mechanism of action, and the drug is not currently marketed in the EU. The evidence base is insufficient to justify further investment at this time.
To proceed, the following is needed:
- Mechanism of action (MOA) data for macimorelin (DrugBank query) — currently a blocking/high-severity data gap
- Regulatory safety labeling (warnings, contraindications) — required before any S1 safety screening can proceed
- A literature search specifically targeting “macimorelin” or “ghrelin receptor agonist” AND “hypertrichosis”/”hair growth” to test the mechanistic hypothesis
- Clarification of the original approved indication and formulation (macimorelin is reportedly a single-dose oral diagnostic agent, which would need reformulation for any chronic dermatologic use)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.